{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:10:59Z","timestamp":1777497059198,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,3,28]],"date-time":"2006-03-28T00:00:00Z","timestamp":1143504000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1038\/sj.bjc.6603004","type":"journal-article","created":{"date-parts":[[2006,3,28]],"date-time":"2006-03-28T17:12:08Z","timestamp":1143565928000},"page":"947-954","source":"Crossref","is-referenced-by-count":39,"title":["Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial"],"prefix":"10.1038","volume":"94","author":[{"name":"for the EPO-INT-45 Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P M","family":"Wilkinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Antonopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lahousen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Kosmidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,3,28]]},"reference":[{"issue":"Suppl 1","key":"BF6603004_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000204780","volume":"87","author":"RI Abels","year":"1992","unstructured":"Abels RI (1992) Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 87 (Suppl 1): 4\u201311","journal-title":"Acta Haematol"},{"key":"BF6603004_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1634\/theoncologist.10-9-743","volume":"10","author":"P Barrett-Lee","year":"2005","unstructured":"Barrett-Lee P, Bokemeyer C, Gasc\u00f3n P, Nortier JW, Schneider M, Schrijvers D, Van Belle S, ECAS Advisory Board and Participating Centers (2005) Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 10: 743\u2013757","journal-title":"Oncologist"},{"key":"BF6603004_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1054\/bjoc.1999.0883","volume":"82","author":"PJ Barrett-Lee","year":"2000","unstructured":"Barrett-Lee PJ, Bailey NP, O\u2019Brien ME, Wager E (2000) Large-scale U.K. audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82: 93\u201397","journal-title":"Br J Cancer"},{"key":"BF6603004_CR4","doi-asserted-by":"crossref","unstructured":"Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, Engert A (2005) Erythropoietin for patients with malignant disease. The Cochrane Database of Systematic Reviews 2004, Issue 3, Art. No. CD003407.pub2. DOI: 10.1002\/14651858.CD003407.pub2","DOI":"10.1002\/14651858.CD003407.pub2"},{"key":"BF6603004_CR5","first-page":"13","volume":"34","author":"D Cella","year":"1997","unstructured":"Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34: 13\u201319","journal-title":"Semin Hematol"},{"key":"BF6603004_CR6","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1200\/JCO.2004.12.027","volume":"23","author":"J Chang","year":"2005","unstructured":"Chang J, Couture F, Young S, McWatters KL, Lau CY (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23: 2597\u20132605","journal-title":"J Clin Oncol"},{"key":"BF6603004_CR7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cncr.10763","volume":"95","author":"J Crawford","year":"2002","unstructured":"Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95: 888\u2013895","journal-title":"Cancer"},{"key":"BF6603004_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","volume":"113","author":"F Dammacco","year":"2001","unstructured":"Dammacco F, Castoldi G, R\u00f6djer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113: 172\u2013179","journal-title":"Br J Haematol"},{"key":"BF6603004_CR9","first-page":"151","volume":"9","author":"D Demetri","year":"1999","unstructured":"Demetri D (1999) Quality-of-life benefits of epoetin alfa treatment in chemotherapy-treated anemic patients with gynecologic malignancies. Int Gynecol Cancer Soc 9: 151","journal-title":"Int Gynecol Cancer Soc"},{"key":"BF6603004_CR10","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","volume":"16","author":"GD Demetri","year":"1998","unstructured":"Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412\u20133425","journal-title":"J Clin Oncol"},{"key":"BF6603004_CR11","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","volume":"19","author":"JL Gabrilove","year":"2001","unstructured":"Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875\u20132882","journal-title":"J Clin Oncol"},{"key":"BF6603004_CR12","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","volume":"15","author":"J Glaspy","year":"1997","unstructured":"Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218\u20131234","journal-title":"J Clin Oncol"},{"key":"BF6603004_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1470-2045(02)00846-X","volume":"3","author":"M Harries","year":"2002","unstructured":"Harries M, Gore M (2002a) Part I: chemotherapy for epithelial ovarian cancer\u2013treatment at first diagnosis. Lancet Oncol 3: 529\u2013536","journal-title":"Lancet Oncol"},{"key":"BF6603004_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1470-2045(02)00847-1","volume":"3","author":"M Harries","year":"2002","unstructured":"Harries M, Gore M (2002b) Part II: chemotherapy for epithelial ovarian cancer\u2013treatment of recurrent disease. Lancet Oncol 3: 537\u2013545","journal-title":"Lancet Oncol"},{"key":"BF6603004_CR15","first-page":"107","volume":"6","author":"AP Heintz","year":"2001","unstructured":"Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Sideri M, Pecorelli S (2001) Carcinoma of the ovary. J Epidemiol Biostat 6: 107\u2013138","journal-title":"J Epidemiol Biostat"},{"key":"BF6603004_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","volume":"362","author":"M Henke","year":"2003","unstructured":"Henke M, Laszig R, Rube C, Schafer U, Haase K, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255\u20131260","journal-title":"Lancet"},{"key":"BF6603004_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/annonc\/mdf122","volume":"13","author":"B Holzner","year":"2002","unstructured":"Holzner B, Kemmler G, Greil R, Kopp M, Zeimet A, Raderer M, Hejna M, Zochbauer S, Krajnik G, Huber H, Fleischhacker WW, Sperner-Unterweger B (2002) The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 13: 965\u2013973","journal-title":"Ann Oncol"},{"key":"BF6603004_CR18","first-page":"789","volume":"22","author":"J Janinis","year":"2003","unstructured":"Janinis J, Dafni U, Aravantinos G, Kalofonos HP, Papakostas P, Tsavdaridis D, Koutras A, Samclis G, Tsolakidis D, Fountzilas G (2003) Quality of life (QoL) outcome of epoetin-alfa (EPO-A) in anemic cancer patients undergoing platinum or non-platinum-based chemotherapy: A randomized study conducted by the Hellenic Cooperative Oncology Group. Proc Am Soc Clin Oncol 22: 789 [abstract 3172]","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6603004_CR19","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/cncr.20569","volume":"101","author":"M Jones","year":"2004","unstructured":"Jones M, Schenkel B, Just J, Fallowfield L (2004) Epoetin alfa improves quality of life in patients with cancer \u2013 results of a metaanalysis. Cancer 101: 1720\u20131732","journal-title":"Cancer"},{"key":"BF6603004_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1006\/gyno.1997.4675","volume":"65","author":"C Kurz","year":"1997","unstructured":"Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, Sevelda P (1997) Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 65: 461\u2013466","journal-title":"Gynecol Oncol"},{"key":"BF6603004_CR21","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1002\/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5","volume":"73","author":"C Leitgeb","year":"1994","unstructured":"Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73: 2535\u20132542","journal-title":"Cancer"},{"key":"BF6603004_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(03)01163-X","volume":"4","author":"B Leyland-Jones","year":"2003","unstructured":"Leyland-Jones B (2003) Reflection and reaction: breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459\u2013460","journal-title":"Lancet Oncol"},{"key":"BF6603004_CR23","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","volume":"19","author":"TJ Littlewood","year":"2001","unstructured":"Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865\u20132874","journal-title":"J Clin Oncol"},{"key":"BF6603004_CR24","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","volume":"40","author":"H Ludwig","year":"2004","unstructured":"Ludwig H, Van Belle S, Barrett-Lee P, Birgeg\u00e5rd G, Bokemeyer C, Gasc\u00f3n P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40: 2293\u20132306","journal-title":"Eur J Cancer"},{"key":"BF6603004_CR25","first-page":"621","volume":"46","author":"S Memarzadeh","year":"2001","unstructured":"Memarzadeh S, Berek JS (2001) Advances in the management of epithelial ovarian cancer. J Reprod Med 46: 621\u2013629; discussion 629\u2013630","journal-title":"J Reprod Med"},{"key":"BF6603004_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1537-2995.1995.35595259154.x","volume":"35","author":"K Mohandas","year":"1995","unstructured":"Mohandas K, Aledort L (1995) Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 35: 427\u2013430","journal-title":"Transfusion"},{"issue":"Suppl 5","key":"BF6603004_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/annonc\/13s50168","volume":"13","author":"P Pronzato","year":"2002","unstructured":"Pronzato P, Cortesi E, van der Rijt C, Moreno-Nogueira JA, Raimundo D, Ostler P, Bols A, Rosso R (2002) Early intervention with epoetin alfa in breast caner (BC) patients (pts) undergoing chemotherapy (CT): results of a randomized, multicenter, phase IIIb study (EPO-INT-47 Study Group). Ann Oncol 13 (Suppl 5): 168; Abstract 620O","journal-title":"Ann Oncol"},{"key":"BF6603004_CR28","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1200\/JCO.1999.17.9.2840","volume":"17","author":"I Ray-Coquard","year":"1999","unstructured":"Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot T, Biron P, Blay JY (1999) Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 17: 2840\u20132846","journal-title":"J Clin Oncol"},{"key":"BF6603004_CR29","doi-asserted-by":"crossref","unstructured":"Savonije J, Van Groeningen C, Van Bochove A, Pinedo H, Giaccone G (2004) Early intervention with epoetin-alfa during platinum-based chemotherapy. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No. 14S (July 15 suppl), abstract 8111","DOI":"10.1200\/jco.2004.22.90140.8111"},{"key":"BF6603004_CR30","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/cncr.11616","volume":"98","author":"D Shasha","year":"2003","unstructured":"Shasha D, George MJ, Harrison LB (2003) Once-weekly dosing of epoetin-\u03b1 increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 98: 1072\u20131079","journal-title":"Cancer"},{"key":"BF6603004_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/BF02821936","volume":"15","author":"WW ten Bokkel Huinink","year":"1998","unstructured":"ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJ, Reed NS, Fairlamb DJ, Chan SY, Godfrey KA, Kristensen GB, van Tinteren H, Ehmer B (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15: 174\u2013182","journal-title":"Med Oncol"},{"issue":"Suppl 2","key":"BF6603004_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000067148","volume":"63","author":"GM Thomas","year":"2002","unstructured":"Thomas GM (2002) Raising hemoglobin: an opportunity for increasing survival? Oncology 63 (Suppl 2): 19\u201328","journal-title":"Oncology"},{"key":"BF6603004_CR33","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1200\/JCO.2004.10.020","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23: 2606\u20132617","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6603004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603004","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:20:09Z","timestamp":1684412409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6603004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,28]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["BF6603004"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6603004","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,28]]}}}